组织型等离子体激活剂与等离子体抑制剂的相互作用及其药理学影响
1Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.
Circulation
|March 1, 1988
概括
组织类型等离子体激活剂 (t-PA) 输液在患者中与等离子体抑制剂形成复合物,主要是PAI-1,降低纤维解质活性. 子研究显示了不同的复杂形成,突出了特定物种的相互作用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 组织类型的等离子体激活剂 (t-PA) 对于纤维素分解至关重要.
- 了解t-PA与血抑制剂的相互作用对于治疗疗效至关重要.
- 血原激活剂抑制剂-1 (PAI-1) 是t-PA活性的一个关键调节剂.
研究的目的:
- 为了研究输注的t-PA和血抑制剂之间的相互作用.
- 为了评估这些相互作用对纤维素分析活性的影响.
- 为了比较患者和子的t-PA抑制剂复合体形成.
主要方法:
- 测定t-PA抗原,PAI-1活性和t-PA抑制剂复合物在连续血样本中的测定.
- 免疫沉以验证t-PA-PAI-1复合体的存在.
- 对自由PAI-1活性进行光谱光度测定.
- 对t-PA特定活动的分析.
主要成果:
- 在患者中,内源的t-PA主要以PAI-1的复合体形式循环.
- 输注的t-PA与PAI-1,α2-抗等离子素和C1-雌激酶抑制剂形成复合体.
- 在47%的患者中,自由PAI-1活性在输液后增加,与减少的t-PA特异性活性相关.
- 子输液显示t-PA复杂化主要与α2-抗等离子素和C1-雌激酶抑制剂,而不是PAI-1.
结论:
- 输注的t-PA在患者中与血抑制剂形成显著的复合物,特别是PAI-1.
- 这些复合物降低了t-PA的有效纤维分解活性.
- 在t-PA抑制剂复合体形成中存在物种差异,影响体内行为.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...


